Torasemide sustained release tablet and preparation method thereof

The preparation of sustained-release tablets by combining torasemide with polyvinyl acetate phthalate and other materials has solved the problem of short scavenging half-life of torasemide and incomplete release of existing sustained-release preparations, and achieved the following 24 The sustained release effect of complete release within hours improves medication compliance and stability.

CN118903034APending Publication Date: 2024-11-08THE FIRST PEOPLES HOSPITAL OF CHUNAN COUNTY (CHUNAN BRANCH OF ZHEJIANG PROVINCIAL PEOPLES HOSPITAL)
View PDF 7 Cites 0 Cited by

Patent Information

Application Number
CN202411279413.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-12
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The short half-life of torasemide leads to the need for frequent medication use. Long-term medication may bring about major side effects. The existing sustained-release preparations cannot be fully released within 24 hours, affecting drug compliance.

Method used

Using a combination of torasemide, polyvinyl acetate phthalate, carbomer, binder, diluent and lubricant, mix pressure with carbomer, diluent and lubricant after granulation and drying Tablets, prepare sustained-release tablets that can be fully released within 24 hours.

Benefits of technology

It achieves smooth dissolution and stable quality of torasemide sustained-release tablets, reduces the number of medications, improves the compliance of patients with long-term medication, and has a simple preparation process and low cost, which is suitable for industrial production.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005041175700000011
    Figure BDA0005041175700000011
  • Figure BDA0005041175700000031
    Figure BDA0005041175700000031
  • Figure BDA0005041175700000032
    Figure BDA0005041175700000032
Patent Text Reader

Abstract

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to a torasemide sustained-release tablet and a preparation method thereof. The sustained-release tablet comprises torasemide, polyvinyl acetate phthalate, carbomer, an adhesive, a diluent and a lubricant. The sustained-release tablet is high in content uniformity, good in stability and capable of being completely released within 24 h, the medicine taking frequency is reduced, and the long-term medicine taking compliance of a patient is improved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to a torsemide sustained-release tablet and a preparation method thereof. Background Art

[0002] Torsemide, chemical name N-[[(1-methylethyl)amino]carbonyl]-4-[(3-methylphenyl)amino]-3-pyridinesulfonamide, molecular formula: C 16 H 20 N4O3S, molecular weight: 348.43, structural formula:

[0003]

[0004] Torsemide is a sulfonylurea pyridine diuretic that mainly acts on the thick ascending limb of the loop of Henle, inhibiting Na + / K + / 2Cl - Carrier system, making Na in urine + , K + , Cl - It increases the excretion of blood and water but has no significant effect on the glomerular filtration rate, renal plasma flow or acid-base balance in the body. It is clinically used for patients with edema caused by congestive heart failure, renal failure and kidney disease, and can also be used for patients with essential hypertension. The elimination half-life of torsemide in the blood is 2.2 to 5 hours. In order to maintain the trough concentration, the dosage must be increased. Long-term use may bring greater side effects. According to the treatment principle of antihypertensive treatment, antihypertensive treatment requires long-term medication and stable blood pressure reduction. The development of torsemide sustained-release preparations is of great significance.

[0005] Torsemide is a low water-soluble substance. When developing a sustained-release preparation of torsemide, it is necessary to screen suitable excipients and preparation processes so that torsemide has good stability and stable dissolution and can be fully absorbed after oral administration. In response to these problems, current researchers have also disclosed many patents and documents.

[0006] CN200510014813.7 discloses a sustained-release tablet containing torasemide as an active ingredient, which is composed of torasemide as an active ingredient, a sustained-release material and other auxiliary materials. The weight ratio of active ingredient torasemide: sustained-release material: common auxiliary materials is 1: 0.2-20: 10-200, preferably 1: 0.5-10: 20-100. The torasemide sustained-release tablet prepared by the present invention releases the drug steadily, which is beneficial to reduce the fluctuation of the drug in the body, thereby achieving a stable blood pressure reduction, and is more suitable for the medication of hypertensive patients. The sustained-release material described in the present invention is a combination of one or more of acrylic resin and cellulose. The acrylic resin is a combination of one or more of a copolymer of methacrylic acid and ethyl acrylate, a copolymer of methacrylic acid and methyl acrylate, and a copolymer of ethyl acrylate, methyl methacrylate and trimethylaminoethyl methacrylate. The cellulose is a combination of one or more of methyl cellulose, ethyl cellulose and hydroxypropyl methylcellulose. However, the sustained-release preparation cannot be completely released within 24 hours, which affects the compliance of medication.

[0007] CN200510014814.1 discloses a sustained-release micropill containing torasemide active ingredient, which is composed of drug-containing micropills and a controlled release layer. Its preparation method comprises: after blank pill core is coated with torasemide or adjuvants are mixed with drugs to form micropills, drug-containing micropills are obtained; after blockers, pore-forming agents, plasticizers or anti-adherent agents are made into coating liquid, they are sprayed on the outer layer of drug-containing micropills in a coating pan or a fluidized bed to make sustained-release micropills. The prepared sustained-release micropills can effectively control the release of drugs within a certain period of time, maintain a stable effective blood drug concentration, and no burst release phenomenon occurs.

[0008] CN200580009389.5 discloses a sustained-release diuretic composition containing torsemide as an active ingredient, wherein the matrix-forming polymer is selected from polymer components including acrylic acid, cellulose, glycerol behenate, guar gum, xanthan gum, chitosan, gelatin, polyvinyl alcohol, etc., and mixtures thereof.

[0009] CN201110082398.4 invented a gastric floating tablet containing torsemide, which is realized by the following technical scheme: after the prescribed amount of torsemide, chitosan, glyceryl behenate, calcium carbonate, magnesium carbonate and mannitol are mixed evenly, sieved evenly with 80 mesh, the prescribed amount of micro powder silica gel and sodium lauryl sulfate are added and mixed evenly, and the tablets are directly pressed by dry method to obtain the tablets. The release degree in 1000ml of hydrochloric acid solution (pH=1.0), water, acetate buffer (pH=5.0) and phosphate buffer (pH=7.2) as solvents respectively reaches more than 96% in 12 hours.

[0010] CN201610481309.6 discloses a torasemide tablet. The torasemide tablet is a preparation made with a new crystalline torasemide as the main component. A new crystalline torasemide prepared by patent CN201610363797.0 has the characteristics of good stability, high purity, high yield, and mild crystallization conditions, and the crystalline form has brought great improvements to the stability, dissolution and water solubility of the preparation. In the absence of a blocker, it can also have a sustained release effect, reduce the use of blockers, reduce toxic side effects, and is very suitable for clinical application.

[0011] CN202211155247.1 discloses a torsemide tablet, the torsemide tablet includes the following components in parts by weight: 4.2-4.6 parts of torsemide microcapsules, 0.42-0.46 parts of lactase, 12.4-12.8 parts of lactose, 3-5 parts of hypromellose, 2.2-2.4 parts of ethylcellulose, 0.4-0.6 parts of sodium lauryl sulfate, 1.4-1.8 parts of magnesium stearate, 2.6-3.4 parts of talcum powder, the torsemide microcapsules include capsule wall and capsule core, the components of the capsule wall include calcium alginate, and the components of the capsule core include torsemide. While adding lactose to torsemide tablets, lactase is also added, and lactase can promote the hydrolysis of lactose, help reduce the possibility of lactose-induced gastrointestinal disorders, and facilitate the absorption of torsemide by the intestinal tract of the patient taking the medicine. While adding lactase, the present application stores torsemide in a microcapsule structure, and utilizes the microcapsule structure to achieve sustained release of torsemide.

[0012] Through the above patented process technology and the effect of sustained-release tablets, it is of great significance to provide a torasemide sustained-release tablet with complete release, good stability and simple preparation process. Summary of the invention

[0013] In view of the shortcomings of torasemide sustained-release preparations in the prior art, the present invention provides a torasemide sustained-release tablet, which has smooth dissolution, stable quality, simple preparation process, low cost and is easy for industrial production.

[0014] The technical solution of the present invention is:

[0015] A torasemide sustained-release tablet comprises torasemide, polyvinyl acetate phthalate, carbomer, a binder, a diluent and a lubricant.

[0016] Preferably, the binder in the sustained-release tablet is one or a combination of polyvinyl pyrrolidone K30 and polyethylene glycol 400. Preferably, the combination of polyvinyl pyrrolidone K30 and polyethylene glycol 400 is used.

[0017] Preferably, the diluent in the sustained-release tablet is one or a combination of lactose, mannitol, crystalline cellulose, silicon dioxide, and calcium hydrogen phosphate.

[0018] Preferably, in the sustained-release tablet, the lubricant is selected from one or more of sodium stearyl fumarate, stearic acid, magnesium stearate or talc.

[0019] Preferably, the sustained-release tablet contains the following components by weight:

[0020]

[0021] Preferably, the sustained-release tablet contains the following components by weight:

[0022]

[0023] Preferably, the sustained-release tablet contains the following components by weight:

[0024]

[0025]

[0026] The present invention also provides a method for preparing the torsemide sustained-release tablets, comprising the following steps:

[0027] 1) mixing torsemide and polyvinyl acetate phthalate for standby use;

[0028] 2) preparing a binder solution with an ethanol aqueous solution, and granulating, granulating, and drying the torasemide mixture;

[0029] 3) The granules prepared in step 2) are mixed with carbomer, a diluent and a lubricant, and the mixture is tableted to obtain a sustained-release tablet.

[0030] Compared with the prior art, the present invention has the following outstanding advantages:

[0031] 1. The sustained-release preparation obtained by the present invention has high content uniformity and good stability, can be completely released within 24 hours, reduces the number of medications, and improves the patient's compliance with long-term medication. DETAILED DESCRIPTION

[0032] The following specific implementation modes are listed to further illustrate the present invention, but do not limit the scope of the present invention in any way. Those skilled in the art can make various modifications or improvements based on the basic idea of ​​the present invention, but as long as they do not deviate from the basic idea of ​​the present invention, they are all within the scope of the present invention.

[0033] Example 1

[0034]

[0035] 2) Preparation process

[0036] 1) mixing torsemide and polyvinyl acetate phthalate for standby use;

[0037] 2) preparing a binder solution with polyvinyl pyrrolidone K30 and polyethylene glycol 400 using a 30% by mass ethanol aqueous solution, and granulating, granulating, and drying the mixed material of torsemide in step 1);

[0038] 3) The granules prepared in step 2) are mixed with carbomer, crystalline cellulose and magnesium stearate, and the mixture is tableted to obtain a sustained-release tablet.

[0039] Example 2

[0040]

[0041] 2) Preparation process, as in Example 1.

[0042] Example 3

[0043]

[0044] 2) Preparation process, as in Example 1.

[0045] Example 4

[0046]

[0047]

[0048] 2) Preparation process, as in Example 1.

[0049] Example 5

[0050]

[0051] 2) Preparation process, as in Example 1.

[0052] Example 6

[0053]

[0054] 2) Preparation process, as in Example 1.

[0055] Example 7

[0056]

[0057] 2) Preparation process, as in Example 1.

[0058] Verification Example

[0059] Experimental Example 1: Investigation of in vitro release characteristics

[0060] Dissolution test: Take the tablets obtained in each embodiment 1-7, refer to the test device of the second method of the fourth part 0931 dissolution determination method of the 2020 edition of the Chinese Pharmacopoeia, and use 0.01mol / L dilute hydrochloric acid as the solvent and pH6.8 phosphate buffer as the dissolution medium, the speed is 60 revolutions per minute, and 5mL is sampled at 1, 2, 4, 6, 8, 12, 18, 22, and 24h (the same amount of medium is added in time), filtered through a 0.45μm microporous membrane, and high performance liquid chromatography is used. Kromasil C18 column (4.6mm×250mm, 5μm) is used as the chromatographic column, the mobile phase is 0.02mol / L potassium dihydrogen phosphate (pH=3.0): acetonitrile (volume ratio 3:1), the flow rate is 1.0ml / min, and the detection wavelength is 291nm for determination. The results of the determination are shown in Table 1.

[0061] Table 1 Dissolution test results of the obtained preparations

[0062]

[0063]

[0064] The results show that the preparations obtained in Examples 1 to 7 can stably release the drug within 24 hours, playing a role of sustained release, and the drug can be completely released within 24 hours.

[0065] Experimental Example 2: Stability study of the preparations obtained in Examples 1 to 7.

[0066] The finished products of the preparations obtained in Examples 1 to 7 were placed at a temperature of 40±2°C and a relative humidity of 75±5% (accelerated) for 6 months. Samples were taken at the end of the 0th, 3rd and 6th months, and the maximum single impurity, total impurities and content were determined. The results are shown in Table 2.

[0067] Table 2 Stability test results of the obtained preparations

[0068]

[0069] The results show that the growth of impurities and the change of content of the preparations obtained in Examples 1 to 7 after being placed under accelerated conditions all meet the quality requirements, which is sufficient to show that the preparations obtained in the present invention have high stability.

Claims

1. A torasemide sustained-release tablet, characterized in that: The sustained-release tablet comprises torsemide, polyvinyl acetate phthalate, carbomer, a binder, a diluent and a lubricant.

2. The sustained-release tablet according to claim 1, characterized in that The binder in the sustained-release tablet is one or a combination of polyvinyl pyrrolidone K30 and polyethylene glycol 400; preferably a combination of polyvinyl pyrrolidone K30 and polyethylene glycol 400.

3. The sustained-release tablet according to claim 1, characterized in that The diluent in the sustained-release tablet is one or a combination of lactose, mannitol, crystalline cellulose, silicon dioxide and calcium hydrogen phosphate.

4. The sustained-release tablet according to claim 1, characterized in that The lubricant is selected from one or more of sodium stearyl fumarate, stearic acid, magnesium stearate or talc.

5. The sustained-release tablet according to claim 1, characterized in that The sustained-release tablet contains the following components by weight:

6. The sustained-release preparation according to claim 1, characterized in that The sustained-release tablet contains the following components by weight:

7. The sustained-release preparation according to claim 1, characterized in that The sustained-release tablet contains the following components by weight:

8. The sustained-release tablet according to any one of claims 1 to 7, characterized in that: The preparation method of the sustained-release tablet comprises the following steps: 1) mixing torsemide and polyvinyl acetate phthalate for standby use; 2) preparing a binder solution with an ethanol aqueous solution, and granulating, granulating, and drying the torasemide mixture; 3) The granules prepared in step 2) are mixed with carbomer, a diluent and a lubricant, and the mixture is tableted to obtain a sustained-release tablet.

Citation Information

Patent Citations

  • Torasemide gastric-floating tablet and preparation method thereof

    CN102188399A

  • Novel crystal form torasemide

    CN105949115A

  • Torasemide tablet

    CN106038500A

  • Torasemide tablet and preparation method thereof

    CN115414471A

  • Slow release tablet comprising toraesmide active ingredient

    CN1919196A